Total Payments
$2,966
2024 Payments
$377.86
Companies
30
Transactions
153
Medicare Patients
4,504
Medicare Billing
$929,158
Payment Breakdown by Category
Food & Beverage$2,945 (99.3%)
Education$12.84 (0.4%)
Consulting$7.86 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,945 | 151 | 99.3% |
| Education | $12.84 | 1 | 0.4% |
| Consulting Fee | $7.86 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $691.18 | 37 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $317.22 | 17 | $0 (2024) |
| Janssen Biotech, Inc. | $310.20 | 26 | $0 (2023) |
| Boston Scientific Corporation | $231.17 | 3 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $184.66 | 2 | $0 (2023) |
| AIMMUNE THERAPEUTICS, INC. | $160.14 | 2 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $154.01 | 10 | $0 (2024) |
| Gilead Sciences, Inc. | $100.48 | 6 | $0 (2022) |
| Olympus America Inc. | $86.29 | 2 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $70.61 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $377.86 | 15 | AIMMUNE THERAPEUTICS, INC. ($160.14) |
| 2023 | $614.46 | 20 | ABBVIE INC. ($212.86) |
| 2022 | $365.09 | 21 | ABBVIE INC. ($138.14) |
| 2021 | $255.44 | 13 | E.R. Squibb & Sons, L.L.C. ($70.61) |
| 2020 | $187.30 | 9 | Boston Scientific Corporation ($74.98) |
| 2019 | $390.01 | 18 | Janssen Scientific Affairs, LLC ($83.40) |
| 2018 | $218.58 | 13 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($117.46) |
| 2017 | $557.40 | 44 | Janssen Biotech, Inc. ($142.00) |
All Payment Transactions
153 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: Gastroenterology | ||||||
| 12/16/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: LIVER DISEASE | ||||||
| 12/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: Gastroenterology | ||||||
| 06/03/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: VIROLOGY | ||||||
| 05/07/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: Gastroenterology | ||||||
| 05/06/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: ENDOCRINOLOGY | ||||||
| 04/01/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/20/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: INTERNAL MEDICINE | ||||||
| 03/18/2024 | ABBVIE INC. | HUMIRA (Biological), SKYRIZI, RINVOQ | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: IMMUNOLOGY | ||||||
| 03/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.01 | General |
| Category: Immunology | ||||||
| 02/01/2024 | Organon Llc | — | Food and Beverage | In-kind items and services | $11.38 | General |
| 01/29/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $156.43 | General |
| Category: GI | ||||||
| 01/29/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $3.71 | General |
| Category: GI | ||||||
| 01/11/2024 | ABBVIE INC. | CREON (Drug), VIBERZI, LINZESS | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: ENDOCRINOLOGY | ||||||
| 01/09/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/21/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: Gastroenterology | ||||||
| 12/06/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $121.44 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2023 | Boston Scientific Corporation | Axios (Device) | Food and Beverage | In-kind items and services | $108.92 | General |
| Category: Axios_ENDO | ||||||
| 12/03/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: Immunology | ||||||
| 11/08/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $12.33 | General |
| Category: Immunology | ||||||
| 11/01/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $21.42 | General |
| 10/18/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Gastroenterology | ||||||
| 10/17/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: Immunology | ||||||
| 10/04/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/02/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.04 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 836 | 9,227 | $1.2M | $246,820 |
| 2022 | 21 | 1,239 | 10,360 | $1.4M | $280,610 |
| 2021 | 21 | 1,200 | 3,089 | $1.1M | $169,677 |
| 2020 | 23 | 1,229 | 7,148 | $1.0M | $232,051 |
Total Patients
4,504
Total Services
29,824
Medicare Billing
$929,158
Procedure Codes
85
All Medicare Procedures & Services
85 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 18 | 6,600 | $250,800 | $114,608 | 45.7% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 22 | 1,770 | $288,510 | $45,496 | 15.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 214 | 214 | $260,866 | $26,118 | 10.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 90 | 91 | $124,124 | $17,563 | 14.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 44 | 44 | $50,160 | $7,082 | 14.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 96 | 96 | $96,864 | $6,507 | 6.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 50 | 83 | $17,928 | $4,959 | 27.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 27 | 27 | $16,146 | $3,539 | 21.9% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 26 | 29 | $30,160 | $3,259 | 10.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 31 | 31 | $12,524 | $3,034 | 24.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 22 | 31 | $12,400 | $2,888 | 23.3% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 24 | 25 | $18,450 | $2,199 | 11.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $6,585 | $1,871 | 28.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 11 | 11 | $12,540 | $1,856 | 14.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 16 | $5,536 | $1,539 | 27.8% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 11 | 11 | $12,540 | $1,383 | 11.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 21 | 26 | $5,330 | $1,213 | 22.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 12 | $2,832 | $814.32 | 28.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 22 | 31 | $4,278 | $628.50 | 14.7% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2023 | 64 | 64 | $9,792 | $263.28 | 2.7% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2022 | 21 | 7,500 | $285,000 | $130,749 | 45.9% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 26 | 1,580 | $257,540 | $44,944 | 17.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 227 | 227 | $276,713 | $25,862 | 9.3% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 136 | 137 | $186,868 | $25,432 | 13.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 105 | 114 | $115,026 | $8,623 | 7.5% |
About Dr. Paul Petersen, MD
Dr. Paul Petersen, MD is a Specialist healthcare provider based in Lincoln, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/06/2005. The National Provider Identifier (NPI) number assigned to this provider is 1245224336.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Petersen, MD has received a total of $2,966 in payments from pharmaceutical and medical device companies, with $377.86 received in 2024. These payments were reported across 153 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($2,945).
As a Medicare-enrolled provider, Petersen has provided services to 4,504 Medicare beneficiaries, totaling 29,824 services with total Medicare billing of $929,158. Data is available for 4 years (2020–2023), covering 85 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Lincoln, NE
- Active Since 09/06/2005
- Last Updated 09/26/2014
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1245224336
Products in Payments
- STELARA (Biological) $484.40
- XIFAXAN (Drug) $331.76
- RINVOQ (Biological) $262.52
- VOWST (Biological) $160.14
- Entyvio (Biological) $109.07
- Axios (Device) $108.92
- CREON (Drug) $105.04
- ZEPOSIA (Drug) $103.96
- CAPTIVATOR COLD (Device) $74.98
- EVIS EXERA (Device) $70.26
- Creon (Drug) $68.96
- Humira (Biological) $67.39
- Sucraid (Drug) $67.02
- HUMIRA (Biological) $59.76
- DUPIXENT (Biological) $54.77
- Amitiza (Drug) $51.18
- Cimzia (Drug) $48.81
- LINZESS (Drug) $47.85
- SPYGLASS (Device) $47.27
- DIFICID (Drug) $27.98
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Lincoln
David Samani, M.d, M.D
Specialist — Payments: $21,983
Specialist $21,983
Dr. Joseph Camarata, M.d., D.m.d, M.D., D.M.D
Specialist — Payments: $14,221
Specialist $14,221
Dr. Mark Griffin, Md, MD
Specialist — Payments: $8,119
Specialist $8,119
Dr. Kirk Kinberg, M.d, M.D
Specialist — Payments: $4,438
Specialist $4,438
Dr. Clark Antonson, Md, MD
Specialist — Payments: $4,344
Specialist $4,344
Dr. Matthew Hrnicek, Md, MD
Specialist — Payments: $4,123
Specialist $4,123